P

Porton Pharma Solutions Ltd
SZSE:300363

Watchlist Manager
Porton Pharma Solutions Ltd
SZSE:300363
Watchlist
Price: 16.65 CNY 1.46% Market Closed
Market Cap: 9.1B CNY
Have any thoughts about
Porton Pharma Solutions Ltd?
Write Note

Gross Margin
Porton Pharma Solutions Ltd

20.6%
Current
41%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
20.6%
=
Gross Profit
566.5m
/
Revenue
2.8B

Gross Margin Across Competitors

Country CN
Market Cap 9.1B CNY
Gross Margin
21%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 749.1B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Country US
Market Cap 348B USD
Gross Margin
69%
Country US
Market Cap 251.1B USD
Gross Margin
77%
Country CH
Market Cap 200.1B CHF
Gross Margin
73%
Country UK
Market Cap 161.8B GBP
Gross Margin
82%
Country CH
Market Cap 171.5B CHF
Gross Margin
75%
Country US
Market Cap 150.1B USD
Gross Margin
71%
No Stocks Found

Porton Pharma Solutions Ltd
Glance View

Market Cap
9.1B CNY
Industry
Pharmaceuticals

Porton Pharma Solutions Ltd., rooted in the vibrant landscape of China's pharmaceutical sector, has strategically navigated its way to becoming a pivotal player in the global Contract Development and Manufacturing Organization (CDMO) industry. Founded in 2005, the company harnesses the intricate synergy between chemistry and biology to drive its core operations. Porton specializes in providing a comprehensive suite of services ranging from early drug development to commercial-scale manufacturing. The company's business model thrives on forming collaborative partnerships with global pharmaceutical and biotechnology firms, offering customized solutions tailored to specific drug production needs. By acting as an extension of its clients' research and development teams, Porton effectively reduces the time and investment required for its clients to bring new drugs to market, catalyzing its own revenue through long-standing service agreements. The essence of Porton’s value proposition lies in its robust technological capabilities and commitment to compliance with international quality standards, which ensures client trust and repeat business. Porton's facilities are outfitted with cutting-edge technologies that support complex chemical synthesis and advanced bioprocessing, allowing them to expertly handle high-potency and complex molecules. Additionally, the company leverages its strategic geographic advantage in China to offer competitive pricing while maintaining quality excellence, a crucial factor in contracting agreements. Through continuous investments in research and development, and a commitment to operational efficiency, Porton Pharma Solutions Ltd. not only accelerates its clients' drug development timelines but also enhances its own profitability, positioning itself as a leader in the evolving CDMO landscape.

Intrinsic Value
20.76 CNY
Undervaluation 20%
Intrinsic Value
Price
P

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
20.6%
=
Gross Profit
566.5m
/
Revenue
2.8B
What is the Gross Margin of Porton Pharma Solutions Ltd?

Based on Porton Pharma Solutions Ltd's most recent financial statements, the company has Gross Margin of 20.6%.